CD274 and neoplasm: It was recently reported that celastrol can also enhance antitumor immune activation by inducing immunogenic cell death (ICD) and reducing the expression of PD-L1 (Qiu et al., 2021), or by upregulating tumor death receptors and then enhancing T-cell cytotoxicity (Li et al., 2016).